{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:03:54Z","timestamp":1784901834970,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Pfizer Global"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic persistent alopecia areata (CPAA), defined by an episode duration &amp;gt; 12\u2005months, tends not to remit spontaneously and patients with CPAA are candidates for systemic therapy. The burden of CPAA is not entirely explained by the severity of scalp hair loss. CPAA widely affects physical and psychosocial aspects of health and wellbeing. Exploring patients\u2019 perspectives on these domains of impact among those commencing systemic treatments will shed light on patient expectations from systemic treatments and the most relevant patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To understand patients\u2019 perspectives on the key impact domains of CPAA that are the most important motives for patients when deciding whether to commence a systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients receiving systemic therapy for CPAA who completed an online survey that included two patient-reported questionnaires, the Assessment of Quality of Life\u20138 Dimensions (AQoL-8D) and the Alopecia Areata Patient Priority Outcome (AAPPO), were invited to participate in a focus group to explore the key impact domains of AA, beyond scalp hair loss severity, that had led them to commence systemic therapy. Focus group discussions were transcribed and thematically analysed using NVivo v14. Quantitative data were analysed using SPSS v26.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Quantitative data (n = 44 online surveys) revealed significant impairment in psychosocial dimensions, contrary to physical dimensions, in our patients, based on the AQoL-8D. None of the health-related quality of life (HRQoL) dimensions were associated with the extent of scalp hair loss, assessed by the AAPPO. Focus group participants (n = 31) revealed AA-related physical and psychosocial priorities, which emerged as 13 subthemes within three main themes: physical, psycho-emotional and social. Eyelash and eyebrow appearance were the most frequent physical impacts. A sense of frustration and\/or despair and the impact of long-term camouflaging in social activities were the most frequent subthemes within their attributed themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Facial hair loss and various psychosocial domains of HRQoL are key impact domains of AA, other than scalp hair loss, in patients commencing systemic treatments. Perceived domains that were considered important by patients can serve as a foundation of patient-centred criteria of candidacy for systemic treatments, contributing to the timely initiation of systemic treatments in patients suffering from considerable disease burden. Further research should aim at the integration of our findings into the clinical setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag112","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:44:10Z","timestamp":1772801050000},"page":"1419-1426","source":"Crossref","is-referenced-by-count":1,"title":["The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: evaluating patients\u2019 perspectives to guide therapy"],"prefix":"10.1093","volume":"51","author":[{"given":"Emadodin","family":"Darchini-Maragheh","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne , Melbourne, VIC ,","place":["Australia"]},{"name":"Sinclair Dermatology , East Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5318-6553","authenticated-orcid":false,"given":"Anthony","family":"Moussa","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-7153","authenticated-orcid":false,"given":"Meryl","family":"Thomas","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC ,","place":["Australia"]},{"name":"School of Medicine, Monash University , Clayton, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laita","family":"Bokhari","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Jones","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , East Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne , Melbourne, VIC ,","place":["Australia"]},{"name":"Sinclair Dermatology , East Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026072409173435800_llag112-B1","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026072409173435800_llag112-B2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"key":"2026072409173435800_llag112-B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ced\/llae320","article-title":"Assessment of clinician-reported outcome measures for alopecia areata: a systematic scoping review","volume":"50","author":"Darchini-Maragheh","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026072409173435800_llag112-B4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/bjd\/ljaf189","article-title":"Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the Alopecia + Me study","volume":"193","author":"Christou","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026072409173435800_llag112-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jid.2022.08.031","article-title":"Signposts to the promised land in alopecia areata","volume":"143","author":"Wall","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026072409173435800_llag112-B6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2023.5869","article-title":"ASAMI Consensus Survey Study Group. The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity","volume":"160","author":"Moussa","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026072409173435800_llag112-B7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ajd.14556","article-title":"Criteria for commencing and continuing subsidised Janus kinase inhibitor therapy in Australian alopecia areata patients \u2013 results from an Australian expert consensus exercise","volume":"66","author":"Thomas","year":"2025","journal-title":"Australas J Dermatol"},{"key":"2026072409173435800_llag112-B8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2024.6660","article-title":"Alopecia areata-specific patient-reported outcome measures: a systematic review","volume":"161","author":"Darchini-Maragheh","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026072409173435800_llag112-B9","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s11136-021-02822-4","article-title":"COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures","volume":"30","author":"Gagnier","year":"2021","journal-title":"Qual Life Res"},{"key":"2026072409173435800_llag112-B10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations","volume":"89","author":"O\u2019Brien","year":"2014","journal-title":"Acad Med"},{"key":"2026072409173435800_llag112-B11","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s11136-014-0686-8","article-title":"Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D","volume":"23","author":"Richardson","year":"2014","journal-title":"Qual Life Res"},{"key":"2026072409173435800_llag112-B12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13555-021-00508-w","article-title":"Development of the alopecia areata patient priority outcomes instrument: a qualitative study","volume":"11","author":"Winnette","year":"2021","journal-title":"Dermatol Ther"},{"key":"2026072409173435800_llag112-B13","first-page":"1408","article-title":"Are we there yet? Data saturation in qualitative research","volume":"20","author":"Fusch","year":"2015","journal-title":"Qual Rep"},{"key":"2026072409173435800_llag112-B14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/1534484320903890","article-title":"Learning to do qualitative data analysis: a starting point","volume":"19","author":"Lester","year":"2020","journal-title":"Hum Resour Dev Rev"},{"key":"2026072409173435800_llag112-B15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1586\/erp.09.36","article-title":"Health utility and economic analysis: theoretical and practical issues","volume":"9","author":"Payakachat","year":"2009","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026072409173435800_llag112-B16","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s11136-016-1337-z","article-title":"Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data","volume":"25","author":"Maxwell","year":"2016","journal-title":"Qual Life Res"},{"key":"2026072409173435800_llag112-B17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jid.2023.10.027","article-title":"Outcome measures for alopecia areata","volume":"144","author":"Darchini-Maragheh","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2026072409173435800_llag112-B18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026072409173435800_llag112-B19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/bjd.17463","article-title":"Living with alopecia areata: an online qualitative survey study","volume":"180","author":"Davey","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026072409173435800_llag112-B20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjd.14497","article-title":"Alopecia areata and health-related quality of life: a systematic review and meta-analysis","volume":"175","author":"Rencz","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026072409173435800_llag112-B21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/ajd.14311","article-title":"Health-related quality of life of adult and adolescent patients living with alopecia areata in Australia","volume":"65","author":"Sinclair","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026072409173435800_llag112-B22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","article-title":"\u201cYou lose your hair, what\u2019s the big deal?\u201d I was so embarrassed, I was so self-conscious, I was so depressed\u2019: a qualitative interview study to understand the psychosocial burden of alopecia areata","volume":"4","author":"Aldhouse","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2026072409173435800_llag112-B23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4278\/0890-1171-12.1.38","article-title":"The transtheoretical model of health behavior change","volume":"12","author":"Prochaska","year":"1997","journal-title":"Am J Health Prom"},{"key":"2026072409173435800_llag112-B24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bodyim.2009.03.004","article-title":"The lived experience of alopecia areata: a qualitative study","volume":"6","author":"Welsh","year":"2009","journal-title":"Body Image"},{"key":"2026072409173435800_llag112-B25","doi-asserted-by":"crossref","first-page":"e015468","DOI":"10.1136\/bmjopen-2016-015468","article-title":"A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia","volume":"7","author":"Montgomery","year":"2017","journal-title":"BMJ Open"},{"key":"2026072409173435800_llag112-B26","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s11136-024-03645-9","article-title":"Estimation of health utility values for alopecia areata","volume":"33","author":"Aggio","year":"2024","journal-title":"Qual Life Res"},{"key":"2026072409173435800_llag112-B27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/jvc2.591","article-title":"An evaluation of generic and disease-specific patient-reported outcome measures to assess the impact of percentage of scalp hair loss on health-related quality of life in a European population","volume":"4","author":"Hanson","year":"2025","journal-title":"JEADV Clin Pract"},{"key":"2026072409173435800_llag112-B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40257-024-00899-4","article-title":"Patient-reported hair loss and its impacts as measured by the alopecia areata patient priority outcomes instrument in patients treated with ritlecitinib: the ALLEGRO Phase 2b\/3 randomized clinical trial","volume":"26","author":"Sinclair","year":"2025","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag112\/67282300\/llag112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1419\/67282300\/llag112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/8\/1419\/67282300\/llag112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:41Z","timestamp":1784899061000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/8\/1419\/8512490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag112","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,9]]}}}